A Phase 3 interventional study of montelukast sodium and Comparator: pranlukast in Rhinitis, Allergic, Seasonal, sponsored by Organon and Co. Completed. Open to participants aged 15 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-08-15.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
The purpose of this trial is to evaluate the efficacy and safety of an investigational drug in adult patients with allergic rhinitis.
396 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
This study's enrollment of 1,375 is above the median of 136 across 360 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Browse Rhinitis, Allergic, Seasonal studies →Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 18 (82%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
montelukast sodium 5 mg, QD 2-weeks
Drug: montelukast sodium
montelukast sodium 10 mg QD 2-weeks
Drug: montelukast sodium
Pranlukast 225 mg BID 2-weeks
Drug: Comparator: pranlukast
montelukast sodium; 5 mg, 10 mg QD 2-weeks.
Also known as: MK0476, Singulair
Pranlukast 225 mg BID 2-weeks.
Composite Nasal Symptom Score
Daytime nasal symptom score, Nighttime nasal symptom score
No study locations are listed for this record.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Montelukast
Rhinitis, Allergic, Seasonal →